HGH 191AA (Somatrompin)

HGH 191AA, also known as Somatropin, is a recombinant form of human growth hormone identical to the endogenous 191-amino acid growth hormone produced by the anterior pituitary gland. Specifically, as the intact, full-length form of somatotropin, HGH 191AA stands as one of the most extensively researched protein hormones in medicine and life sciences, supported by decades of preclinical and clinical study across diverse physiological domains.

Mechanistically, research has examined its profound influence on linear bone growth, skeletal muscle protein anabolism, and lipolysis, alongside its essential role in modulating carbohydrate, lipid, and protein metabolism. Because it binds directly to cell-surface growth hormone receptors across multiple target tissues, HGH 191AA triggers systemic signaling cascades, most notably stimulating hepatic synthesis and release of insulin-like growth factor-1 (IGF-1).

Consequently, this systemic upregulation of IGF-1 mediates many of growth hormone’s primary downstream anabolic and tissue-regenerative effects. In addition, researchers have investigated its physiological role in the context of age-related declines in GH secretion, examining whether supplementation can reverse changes in body composition, bone mineral density, and lipid metabolism associated with the somatopause. Furthermore, ongoing studies continue to explore its nuanced actions on cellular repair, nitrogen retention, and metabolic homeostasis. Overall, its defining role in growth biology, endocrine signaling, and metabolic regulation makes HGH 191AA a foundational research compound in physiology and biogerontology.